The primary outcome would be change in depressive symptom severity over 812 weeks using validated clinician-rated scales, with secondary outcomes including response and remission rates, anxiety, fatigue, cognitive function, sleep quality, and quality of life
Badania opublikowane w 2017 r
Chembiochem 2020, 21 (15), 21492160
Acknowledgements The infrastructure for the NESDA study ( is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10-000-1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Rob Giel Onderzoekscentrum)